Comparative Pharmacology
Head-to-head clinical analysis: ERYTHROCIN STEARATE versus ILOSONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHROCIN STEARATE versus ILOSONE.
ERYTHROCIN STEARATE vs ILOSONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It may also act as a motilin receptor agonist, stimulating gastrointestinal motility.
Erythromycin (ILOSONE) binds to the 50S subunit of bacterial ribosomes, inhibiting peptide chain elongation and protein synthesis by blocking translocation.
250-500 mg orally every 6 hours for mild to moderate infections; up to 4 g/day for severe infections.
Erythromycin (Ilosone) base or stearate: 250-500 mg orally every 6 hours. Estolate: 250-500 mg orally every 6 hours. Maximum dose 4 g/day.
None Documented
None Documented
1.5-2 hours in adults; prolonged to 5-6 hours in severe hepatic impairment. In anuria, half-life not significantly affected.
1.5-2 hours in adults; prolonged in hepatic impairment (up to 5-6 hours)
Primarily biliary-fecal (90-95% as unchanged drug and metabolites); renal excretion accounts for 2-15%.
Renal (2-5% unchanged), biliary/fecal (majority, >90% as metabolites and unchanged drug)
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic